Cargando…

Inequity in insurance coverage for prescription drugs in New Brunswick, Canada

OBJECTIVES: To describe the extent to which New Brunswick residents reported having drug insurance coverage supplementary to Canadian Medicare; to examine associations between socioeconomic and demographic characteristics, health status, language identity, and having reported such coverage; and to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayodele, Busola, Guo, Elaine Xiaoyu, Sweetman, Arthur, Guindon, G. Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263015/
https://www.ncbi.nlm.nih.gov/pubmed/35488147
http://dx.doi.org/10.17269/s41997-022-00639-3
_version_ 1784742630161121280
author Ayodele, Busola
Guo, Elaine Xiaoyu
Sweetman, Arthur
Guindon, G. Emmanuel
author_facet Ayodele, Busola
Guo, Elaine Xiaoyu
Sweetman, Arthur
Guindon, G. Emmanuel
author_sort Ayodele, Busola
collection PubMed
description OBJECTIVES: To describe the extent to which New Brunswick residents reported having drug insurance coverage supplementary to Canadian Medicare; to examine associations between socioeconomic and demographic characteristics, health status, language identity, and having reported such coverage; and to document any changes in coverage associated with the introduction of the New Brunswick Drug Plan in 2014. METHODS: We used repeated cross-sectional data for New Brunswick from eight cycles of the Canadian Community Health Survey from 2007 to 2017 and undertook logistic regression analysis. RESULTS: We found statistically significant, substantial and policy-relevant socioeconomic differences in the reporting of prescription drug insurance coverage among those 25–64 years and those ≥ 65 years of age, and an increasing reliance on private drug insurance over time. We found that individuals in the second decile of household income were particularly vulnerable to reporting neither public nor private drug coverage. The introduction of the New Brunswick Drug Plan in 2014 does not appear to have led to increased public drug coverage; however, from 2014, the decreasing trend in public drug coverage appears to have ceased. Those who reported lower health status usually had lower odds of reporting private drug coverage but higher odds of reporting public drug coverage. Driven by differences in private coverage, we found that relative to anglophones, francophones were less likely to report any drug coverage. CONCLUSION: Our findings emphasize the shortcomings of drug insurance systems such as that introduced in New Brunswick and substantiate calls for a universal drug program. New Brunswick’s increasing reliance on private drug insurance is of concern and warrants additional research.
format Online
Article
Text
id pubmed-9263015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92630152022-07-09 Inequity in insurance coverage for prescription drugs in New Brunswick, Canada Ayodele, Busola Guo, Elaine Xiaoyu Sweetman, Arthur Guindon, G. Emmanuel Can J Public Health Quantitative Research OBJECTIVES: To describe the extent to which New Brunswick residents reported having drug insurance coverage supplementary to Canadian Medicare; to examine associations between socioeconomic and demographic characteristics, health status, language identity, and having reported such coverage; and to document any changes in coverage associated with the introduction of the New Brunswick Drug Plan in 2014. METHODS: We used repeated cross-sectional data for New Brunswick from eight cycles of the Canadian Community Health Survey from 2007 to 2017 and undertook logistic regression analysis. RESULTS: We found statistically significant, substantial and policy-relevant socioeconomic differences in the reporting of prescription drug insurance coverage among those 25–64 years and those ≥ 65 years of age, and an increasing reliance on private drug insurance over time. We found that individuals in the second decile of household income were particularly vulnerable to reporting neither public nor private drug coverage. The introduction of the New Brunswick Drug Plan in 2014 does not appear to have led to increased public drug coverage; however, from 2014, the decreasing trend in public drug coverage appears to have ceased. Those who reported lower health status usually had lower odds of reporting private drug coverage but higher odds of reporting public drug coverage. Driven by differences in private coverage, we found that relative to anglophones, francophones were less likely to report any drug coverage. CONCLUSION: Our findings emphasize the shortcomings of drug insurance systems such as that introduced in New Brunswick and substantiate calls for a universal drug program. New Brunswick’s increasing reliance on private drug insurance is of concern and warrants additional research. Springer International Publishing 2022-04-29 /pmc/articles/PMC9263015/ /pubmed/35488147 http://dx.doi.org/10.17269/s41997-022-00639-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Quantitative Research
Ayodele, Busola
Guo, Elaine Xiaoyu
Sweetman, Arthur
Guindon, G. Emmanuel
Inequity in insurance coverage for prescription drugs in New Brunswick, Canada
title Inequity in insurance coverage for prescription drugs in New Brunswick, Canada
title_full Inequity in insurance coverage for prescription drugs in New Brunswick, Canada
title_fullStr Inequity in insurance coverage for prescription drugs in New Brunswick, Canada
title_full_unstemmed Inequity in insurance coverage for prescription drugs in New Brunswick, Canada
title_short Inequity in insurance coverage for prescription drugs in New Brunswick, Canada
title_sort inequity in insurance coverage for prescription drugs in new brunswick, canada
topic Quantitative Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263015/
https://www.ncbi.nlm.nih.gov/pubmed/35488147
http://dx.doi.org/10.17269/s41997-022-00639-3
work_keys_str_mv AT ayodelebusola inequityininsurancecoverageforprescriptiondrugsinnewbrunswickcanada
AT guoelainexiaoyu inequityininsurancecoverageforprescriptiondrugsinnewbrunswickcanada
AT sweetmanarthur inequityininsurancecoverageforprescriptiondrugsinnewbrunswickcanada
AT guindongemmanuel inequityininsurancecoverageforprescriptiondrugsinnewbrunswickcanada